基于循证医学的糖尿病及其并发症中西医协同治疗体系构建与挑战

Construction and Challenges of an Evidence-Based Integrated Chinese and Western Medicine Therapeutic System for Diabetes Mellitus and Its Complications

摘要: 糖尿病作为全球增长最快的代谢性疾病，其病理机制复杂性和并发症多样性对现有治疗体系提出严峻挑战。本文系统综述2019~2024年中西医治疗糖尿病及其并发症的研究进展，整合现代医学精准靶向治疗与传统中医整体调节的优势。西医治疗通过新型药物(如SGLT-2抑制剂恩格列净降低心血管死亡率38%)与人工胰腺技术(血糖达标时间延长35%)实现快速控糖，但单一干预难以逆转代谢记忆效应；中医基于“三焦辨证”理论，以葛根芩连汤(下调TXNIP/NLRP3炎症轴)、六味地黄丸(提升β细胞功能指数26.5%)等多靶点调控改善胰岛素抵抗。在并发症防治中，中西医协同方案展现显著临床优势：RAAS抑制剂联用黄芪–大黄药可使糖尿病肾病蛋白尿减少52%，α-硫辛酸联合针灸提升周围神经传导速度0.8 m/s (P < 0.01)。当前研究通过人工智能舌脉诊系统(准确率89%)与肠道菌群–代谢组学交叉分析，推动辨证客观化与疗效预测精准化。尽管面临中药复方质量控制(活性成分差异达3.8倍)、机制阐释深度不足(仅12%复方明确关键靶点)等挑战，多组学技术与真实世界证据体系的融合为中西医整合治疗提供了新路径。本文为构建个体化糖尿病管理方案提供理论依据，并指明未来研究应聚焦国际标准互认(如ICH Q13)与转化医学平台建设。

Abstract: Diabetes mellitus, as one of the fastest-growing metabolic disorders globally, poses significant challenges due to its complex pathogenesis and diverse complications. This review synthesizes recent advances (2019~2024) in integrated Chinese and western medicine for diabetes management, highlighting synergistic mechanisms and clinical translation pathways. Western medicine achieves rapid glycemic control through novel agents (e.g., SGLT-2 inhibitors reduce cardiovascular mortality by 38%) and advanced technologies like artificial pancreas systems (35% extension in time-in-range). However, monotherapy often fails to reverse metabolic memory. Traditional Chinese medicine (TCM), guided by the “Triple Burner Syndrome Differentiation” theory, employs multitarget regulation via classical formulas: Gegen Qinlian Decoction downregulates the TXNIP/NLRP3 inflammasome axis, while Liuwei Dihuang Wan improves β-cell function by 26.5%. For complications, integrated strategies demonstrate marked efficacy—RAAS inhibitors combined with Astragalus-Rheum palmatum pairs reduce diabetic nephropathy proteinuria by 52%, and α-lipoic acid with acupuncture enhances peripheral nerve conduction velocity by 0.8 m/s (P < 0.01). Cutting-edge technologies, including AI-assisted tongue/pulse diagnostics (89% accuracy) and gut microbiota-metabolomics profiling, enable objective syndrome differentiation and personalized prediction. Despite challenges such as batch-to-batch variability in herbal formulas (3.8-fold differences in active components) and fragmented mechanistic insights (only 12% of formulas have clarified targets), emerging multi-omics integration and real-world evidence frameworks offer transformative solutions. This review underscores the imperative for global standard harmonization (e.g., ICH Q13) and translational platforms to advance integrated diabetes care, ultimately benefiting 537 million patients worldwide.